Assays to lead the way: High throughput screening and probe discovery at the NIH

Wednesday, September 24, 2014 — Concurrent Symposia Session IV
12:00 p.m. – 2:00 p.m.	Classrooms 1 and 2

Co-chairs

• Marc Ferrer, NCATS
• Matthew Hall, NCI

Program

High-throughput screening (HTS) has been widely implemented in drug discovery and has become one of the major sources of therapeutic small molecule leads. Success in screening has been driven by progress in automation technology and assay development, at biochemical, cellular and model organism-based levels. HTS also relies on collaboration between inter-disciplinary teams with expertise in fields including engineering, biology, informatics, and chemistry. A number of HTS efforts exist at institutes within the NIH, including at NCATS. This symposium will highlight research related to screening development and discovery at the NIH, and is of broad relevance to the biomedical research community interested in biological target identification, assay development and best practice in the development of probes that arise from high-throughput screening.

NCATS: Collaborative opportunities in the early discovery space
Anton Simeonov, NCATS

Identifying therapeutic leads for Gauche disease and for Parkinsonism: New strategies and new models
Ellen Sidransky, NHGRI

Integrative approaches toward small molecule therapeutics
Craig Thomas, NCATS

Forward chemical genetics of anti-HCV therapy: rational or irrational drug design
Jake Liang, NIDDK

back to top